Dx & Vx Co., Ltd. (KOSDAQ:180400)

Market Cap	481.81B +432.9%
Revenue (ttm)	29.36B -13.5%
Net Income	-29.04B
EPS	-587.00
Shares Out	98.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,605
Average Volume	324,841
Open	5,050.00
Previous Close	5,020.00
Day's Range	4,850.00 - 5,150.00
52-Week Range	1,319.00 - 5,360.00
Beta	0.23
RSI	56.26
Earnings Date	May 14, 2026

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2001
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 180400

Financial Performance

In 2025, Dx & Vx's revenue was 29.36 billion, a decrease of -13.52% compared to the previous year's 33.95 billion. Losses were -29.04 billion, -38.26% less than in 2024.